CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Pre-Mkt 01-23 04:33:45 EST

1.04

+0.04

+4.00%

High1.12	Low0.9995	Vol70.48K
Open0.9995	D1 Closing1.00	Amplitude12.05%
Mkt Cap7.45M	Tradable Cap4.00M	Total Shares7.17M
T/O74.28K	T/O Rate1.83%	Tradable Shares3.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":1.04,"timestamp":1769115600000,"preClose":1,"halted":0,"volume":70478,"delay":0,"changeRate":0.040000000000000036,"floatShares":3843300,"shares":7167700,"eps":-9.021739,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"01-23 04:33:45 EST","open":0.9995,"high":1.12,"low":0.9995,"amount":74275.5731218,"amplitude":0.1205,"askPrice":1.27,"askSize":200,"bidPrice":0.9145,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.021739,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769178600000},"marketStatusCode":1,"adr":0,"exchange":"AMEX","adjPreClose":1.04,"postHourTrading":{"tag":"盘后","latestPrice":1.0698,"preClose":1.04,"latestTime":"19:50 EST","volume":254,"amount":269.6639,"timestamp":1769129415226,"change":0.0298,"changeRate":0.028654,"amplitude":0.028654},"volumeRatio":0.7332460805870695},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2592595569","title":"Calidi Biotherapeutics Director Allan Camaisa Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592595569","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592595569?lang=en_us&edition=fundamental","pubTime":"2025-12-17 08:37","pubTimestamp":1765931857,"startTime":"0","endTime":"0","summary":"Allan Camaisa, Director of Calidi Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL4ZDLr9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Director Allan Camaisa Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2584550625","title":"Calidi Biotherapeutics Hosts Exclusive Investor Webinar Featuring CEO Eric Poma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584550625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584550625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:01","pubTimestamp":1763384495,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. will host a live investor webinar and Q&A session on November 19, 2025. During the event, CEO Eric Poma will present insights into Calidi's RedTail platform, an engineered viral therapy designed for targeted delivery of genetic medicines to metastatic tumor sites, and share recent preclinical data demonstrating its effectiveness in avoiding immune detection and delivering genetic payloads to tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL2ThLlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","CLDI","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2583124465","title":"Calidi Biotherapeutics reports third quarter net loss of $5.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583124465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583124465?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:31","pubTimestamp":1763069510,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. reported a net loss of $5.2 million for the third quarter ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024. A non-cash charge for deemed dividend on warrants increased the net loss attributable to shareholders to $10.8 million, while there was no such charge in the prior year period. Net loss per share, basic and diluted, was $2.21, down from $7.75 in the third quarter of 2024. Research and development expenses were $2.4 million, up from $2.2 million, and general and administrative expenses were $2.7 million, down from $3.1 million in the comparable period of 2024. The company had approximately $10.4 million in cash at the end of the quarter. Calidi raised $6.9 million in gross proceeds from an underwritten public offering, bringing total gross proceeds in 2025 to $23.0 million. Key business developments included new data presentations on CLD-401, further expansion of the RedTail platform, and the establishment of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL42YSQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2583351265","title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351265","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351265?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:22","pubTimestamp":1763068926,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851012/calidi-biotherapeutics-q3-eps-2-21-misses-1-68-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2583749514","title":"Calidi Biotherapeutics Raises $6.9 Million and Advances RedTail Platform Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583749514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583749514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068533,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced its third quarter 2025 financial results and recent operational highlights. The company raised $6.9 million in gross proceeds through an underwritten public offering with new and existing investors, extending its financial runway and bringing the total gross proceeds raised in 2025 to $23.0 million. Calidi presented new data at the Society of Immunotherapy for Cancer  annual meeting demonstrating that its CLD-401 candidate can protect from immune clearance after systemic administration and effectively express genetic medicines at tumor sites. The company expanded the capabilities of its RedTail platform, including programmable membrane targeting and the addition of multiple payloads. Calidi also established a new Scientific Advisory Board to support the development of CLD-401 and further advance the RedTail platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2zRcn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4585","LU2210149790.SGD","BK4112","CLDI","BK4588"],"gpt_icon":0},{"id":"2583514242","title":"Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514242?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2583277512","title":"Calidi Biotherapeutics Inc - Qtrly Net Loss per Share, Basic and Diluted, Was $2.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583277512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583277512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:15","pubTimestamp":1763068501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA8KCKCW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2582718308","title":"Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582718308","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582718308?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:07","pubTimestamp":1762780034,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced new data on its lead therapeutic candidate, CLD-401, at the 2025 Society of Immunotherapy for Cancer  Annual Meeting. CLD-401, developed using Calidi's RedTail platform, is a tumor-tropic oncolytic virus designed for systemic administration that selectively replicates in tumor cells, induces immune priming at the tumor site, and expresses high levels of IL-15 superagonist in the tumor microenvironment. According to the company, preclinical syngeneic models demonstrated targeted delivery and expression of IL-15 superagonist in tumors with minimal systemic exposure. The latest results were presented at SITC 2025. Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug  application by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL6zwfQb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","CLDI","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2580731748","title":"Calidi Biotherapeutics to Present RedTail Platform at SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731748?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261229,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. will hold an investor event at the Society of Immunotherapy for Cancer  Annual Meeting on Friday, November 7, 2025. The company will present updates on its RedTail platform and lead candidate, CLD-401.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2JQKhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","NDAQ","BK4139","IE00B64PRP62.GBP","BK4112","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2580021363","title":"Calidi Biotherapeutics Selects Matica Bio for CLD-401 Oncolytic Virus Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580021363","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580021363?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174907,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has entered into a strategic partnership with Matica Biotechnology, Inc. for the development and manufacturing of CLD-401, the first lead candidate from Calidi's RedTail platform. Under the agreement, Matica Bio will provide analytical development, process development, and GMP manufacturing services to support Calidi's IND submission for CLD-401, an oncolytic virus-based therapy designed for cancer treatment. This collaboration leverages Matica Bio's expertise in viral vector manufacturing to advance Calidi's clinical-stage immuno-oncology program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on Nov","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9XL7cH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2580416561","title":"Calidi Biotherapeutics Inc - Following Closing, Nova Cell Is No Longer Subsidiary of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416561?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2580416308","title":"Calidi Biotherapeutics: on Oct 27, Enters Into Sra & Mpa, With Its Majority Owned Unit, Nova Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416308?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580041637","title":"Calidi Biotherapeutics Inc - Sold and Transferred 22.5 Mln Shares of Nova Cell for $6 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580041637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580041637?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:21","pubTimestamp":1761942088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC1ON:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2580141501","title":"Calidi Biotherapeutics Sells Majority Stake in Nova Cell for $6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141501","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580141501?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:16","pubTimestamp":1761941766,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has completed an asset transaction with its majority-owned subsidiary, Nova Cell, Inc. Under a new Material Purchase Agreement, Calidi sold and transferred certain materials to Nova Cell, with Nova Cell also assuming specific defined liabilities and agreeing to usage restrictions. The agreement replaces a previous intellectual property assignment between the parties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1k34LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2579457011","title":"Calidi Biotherapeutics Unveils New Data on CLD-401 Tumor Therapy at SITC 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579457011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579457011?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825636,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that new data on its lead therapeutic candidate, CLD-401, will be presented at the Society for Immunotherapy of Cancer  40th Anniversary Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, MD. The presentation, titled \"In Situ Tumor Delivery of IL-15 Superagonist via RedTail Gene Therapy Achieves Durable Tumor Clearance,\" is set for November 7, 2025. CLD-401, developed using Calidi's RedTail platform, is a tumor-tropic oncolytic virus engineered to target metastatic tumor sites, induce immune priming, and deliver high levels of IL-15 superagonist in the tumor microenvironment to activate NK and T-cell responses. The company is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug  application by the end of 2026. Results from the current studies have not yet been presented and will be disclosed at the upcoming SITC meeting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLb2FgZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","CLDI","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2577369024","title":"Press Release: Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2577369024","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577369024?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 22, 2025  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation of its Scientific Advisory Board  comprised of leading industry and academic researchers in with deep expertise in drug development.The SAB will work with Calidi to further develop its RedTail platform and advance CLD-401 into the clinic. RedTail is Calidi's groundbreaking approach to genetic medicines that utilizes an enveloped form of vaccinia virus genetically engineered to overexpress CD55 and avoid immune clearance, allowing for systemic delivery and targeting of genetic medicine payload to sites of disease.CLD-401, the first lead from the RedTail platform, is designed to home to metastatic sites after systemic administration, replicate only in tumors cells, induce an immune priming event at the tumor site, and express high levels of IL-15 superagonist in the tumor microen","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4592","IE000M9KFDE8.USD","LU1883839398.USD","LU0234572021.USD","IE00BLSP4452.SGD","BK4588","BK4232","LU0058720904.USD","BK4568","BK4533","LU1066053197.SGD","LU1057294990.SGD","LU0306806265.USD","LU1066051498.USD","BK4581","LU0868494617.USD","SGXZ57979304.SGD","LU0456855351.SGD","LU0985481810.HKD","LU1023059063.AUD","IE0002270589.USD","LU0306807586.USD","LU0321505439.SGD","LU0321505868.SGD","CLDI","IE00B19Z3B42.SGD","R","LU1894683264.USD","SG9999001176.SGD","BK4585","LU1894683348.USD","BK4534","LU0170899867.USD","SG9999001176.USD","BK4599","BK4139","LU0289739699.SGD","SG9999011175.SGD","LU0122379950.USD","BK4007","BK4022","IE00BBT3K403.USD","IE00BLSP4239.USD","SG9999002232.USD","SG9999003800.SGD","LU0225284248.USD","SG9999013999.USD","BK4550"],"gpt_icon":1},{"id":"2569117467","title":"Calidi Biotherapeutics Announces Management Restructuring: Chief Legal Officer Position Eliminated, Andrew Jackson Appointed Corporate Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2569117467","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569117467?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:42","pubTimestamp":1758642136,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Announces Management Restructuring: Chief Legal Officer Position Eliminated, Andrew Jackson Appointed Corporate Secretary. Calidi Biotherapeutics Inc. has announced changes in its management structure, effective October 17, 2025. The company has decided to eliminate the position of Chief Legal Officer, resulting in the termination of Wendy Pizarro Campbell's employment. This decision aligns with Calidi's ongoing cost-reduction and operating-efficiency initiatives. Andrew Jackson, the Chief Financial Officer, will assume the role of Corporate Secretary. Additionally, Ms. Campbell will continue to provide services to the company under a consulting agreement starting October 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL1GZfhz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2568929148","title":"Calidi Biotherapeutics Inc - Eliminates Chief Legal Officer Position - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2568929148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568929148?lang=en_us&edition=fundamental","pubTime":"2025-09-20 05:04","pubTimestamp":1758315868,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250919:nFWN3V60ZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2563077162","title":"Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2563077162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563077162?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:53","pubTimestamp":1756504389,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. Unveils New Presentation on Advancements in Genetic Medicine Targeting Cancer and Complex Diseases. Calidi Biotherapeutics Inc. has released a corporate presentation detailing advancements in their genetic medicine technology. The company is focused on delivering precise genetic treatments for a variety of complex diseases, including cancer. Their pipeline includes several candidates at various stages of development, such as NeuroNova for glioblastoma and SuperNova for solid tumors. Calidi's innovative approach involves using stem cells loaded with viruses to enhance tumor targeting and protection from immune clearance. Additionally, the RedTail platform employs extracellular enveloped viruses for efficient dissemination. Calidi is also exploring opportunities for non-dilutive grant funding to support their intratumoral approach. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL5SW53G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2562741001","title":"Calidi Biotherapeutics Inc. Files Initial Beneficial Ownership Statement for Lincoln Alternative Strategies LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2562741001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562741001?lang=en_us&edition=fundamental","pubTime":"2025-08-27 21:14","pubTimestamp":1756300476,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. filed an initial statement of beneficial ownership, naming Lincoln Alternative Strategies LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDLbF6Lb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.2},{"period":"3month","weight":-0.3247},{"period":"6month","weight":-0.8813},{"period":"1year","weight":-0.8866},{"period":"ytd","weight":-0.1111}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.18242},{"month":2,"riseRate":0.75,"avgChangeRate":-0.022689},{"month":3,"riseRate":0.5,"avgChangeRate":-0.101198},{"month":4,"riseRate":0.25,"avgChangeRate":-0.200168},{"month":5,"riseRate":0.25,"avgChangeRate":-0.071752},{"month":6,"riseRate":0.75,"avgChangeRate":-0.069766},{"month":7,"riseRate":0.75,"avgChangeRate":0.345315},{"month":8,"riseRate":0.25,"avgChangeRate":-0.291823},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction